Mineralys Therapeutics announced on October 30, 2024, that it has completed enrollment for its pivotal Phase 3 Launch-HTN trial ahead of schedule. This trial is evaluating lorundrostat for the treatment of hypertension.
The early completion of enrollment is a significant operational achievement, indicating efficient progress in the clinical development program. Topline data from the Launch-HTN trial is now anticipated in the mid-first half of 2025.
This advancement brings the company closer to generating crucial efficacy and safety data for lorundrostat, which is essential for its planned New Drug Application submission. The accelerated timeline could potentially expedite the drug's path to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.